WHI-P154 is an inhibitor of Janus-activated kinase JAK3. Also this drug inhibits other common kinases including EGFR, Src, Abl, VEGFR and others. WHI-P154 is potent inhibitor of glioblastoma cell adhesion and migration. Further preclinical development of WHI-P154 may provide the basis for the design of more effective adjuvant chemotherapy programs for glioblastoma multiforme. Treatment of ALK inhibitor, WHI-P154 resulted in the down-regulation of aberrant anaplastic lymphoma kinase (ALK) signaling, shrinkage of tumor, and suppression of metastasis and significantly improved survival of ALK mutant-bearing mice.

PD168393 is potent, cell-permeable, irreversible and selective inhibitor of EGF receptor (EGFR) tyrosine kinase and ErbB2. PD168393 has an IC50 value of 0.70 nM for EGFR, and is inactive against insulin, PDGFR, FGFR and PKC. PD168393 induced cytostatic responses in preclinical models of non-small cell lung cancer, squamous carcinoma, malignant peripheral nerve sheath tumors. Locally administred PD168393 ameliorated excessive reactive astrogliosis and facilitated a more favorable environment for axonal regeneration in the model of spinal cord injury.

Lavendustin B is a weak tyrosine kinase inhibitor that has been used as a negative control for lavendustin A. Lavendustin A strongly inhibits epidermal growth factor receptor-associated tyrosine kinase, competes with ATP, and is noncompetitive with the peptide. Lavendustin B was previously identified as an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF/p75).

Lavendustin C or HDBA (2-hyroxyl-5-(2,5-dihydroxybenzylamino) benzoic acid) is the active pharmacophore of lavendustin A, a tyrosine kinase inhibitor isolated from a butyl acetate extract of Streptomyces griseolavendus.

CL-387785 is irreversible inhibitor of EGF-R kinase

WZ4002 is a covalent pyrimidine inhibitor of EGFR, it demostrated the potency and relative selectivity for mutant EGFR forms. WZ4002 suppresses the growth of EGFR containing cell lines. It was effective in murine models of lung cancer driven by mutant EGFR.